Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEF trial of pirfenidone in progressive non-IPF lung fibrosis
2014-000861-32Phase 2Completed
- Sponsor
- Justus Liebig University Giessen
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary fibrosis (PF), idiopathic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (cHP) and 2 more comparing Pirfenidone with Placebo (2 arms). Primary endpoint: Absolute change in percent predicted forced vital capacity. Started Sep 2015; status: completed.
02
Drugs
pirfenidone
03
Conditions
pulmonary fibrosis (PF)idiopathic nonspecific interstitial pneumonia (NSIP)chronic hypersensitivity pneumonitis (cHP)connective tissue disease-associated interstitial lung disease (CTD-ILD)asbestosis
Beyond the preview
Go deeper on 2014-000861-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000861-32.